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Objective: While much attention has been devoted toward treatment paradigms for idiopathic axillo-subclavian vein
thrombosis (ASVT), little has focused on long-term durability of aggressive treatment and its associated functional
outcomes. The purpose of this study was to review our own surgical therapeutic algorithm and its associated durability
and functional outcomes.
Methods: All patients treated with combined endovascular and open surgery at Dartmouth-Hitchcock Medical Center for
ASVT from 1988 to 2008 were identified. Patient demographics, comorbidities, and operative techniques were recorded.
Patency, freedom from reintervention, and functional outcomes were documented. Follow-up via telephone and clinic
visit allowed quantitative comparison of functional status, pre- and postoperatively.
Results: Thirty-six patients were treated for ASVT throughout the study interval. Seven patients (19.4%) were lost to
follow-up. Most patients were male (66%; N  24); mean age was 32 years. Catheter-directed thrombolysis was utilized
in the majority of patients (83.3%; N  30) with an average time from symptom onset to lysis of 12 days. Surgical
decompression was undertaken in all patients via transaxillary (52%; N  19), supraclavicular (31%; N  11), or
infraclavicular approaches (17%; N  6). Eleven stents were placed in 11 patients (30.5%) for residual stenotic disease.
Mean follow-up was 65 months, with 1- and 5-year overall patency at 100% and 94%, respectively. Freedom from
reintervention was 100% and 74.4% at 1 and 5 years, respectively. Seven patients (19.4%) required postoperative
reintervention with four receiving additional lytic therapy, two requiring a stent, and one venoplasty. At presentation,
65.5% (N  19) of patients were unable to work or perform routine activities. After treatment, 86% (N  25) returned
to their employment and have experienced sustained symptomatic and functional improvement.
Conclusions: Patients with symptomatic idiopathic axillo-subclavian vein thrombosis can expect durable patency with
sustained freedom from reintervention following aggressive combined endovascular and surgical treatment. Good
functional outcomes can be expected in patients with relief of symptoms and return to work. (J Vasc Surg 2010;52:
127-31.)Since its initial description in the latter 19th century by
Sir Paget and Von Schroetter, the therapeutic algorithm for
treatment of effort-induced axillo-subclavian vein throm-
bosis (ASVT) has undergone a considerable evolution.
Early management strategies featuring conservative treat-
ment, including extremity elevation, warm compresses, and
anticoagulation, were supplanted by therapeutic protocols
currently involving antecedent thrombolytic therapy fol-
lowed by staged surgical thoracic outlet decompression.1,2
More recently, attempts to further refine combined endo-
vascular and surgical treatment approaches have been the
subject of many reports, with various authors espousing the
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rithms.1,3-5 By comparison, little attention has been de-
voted to the natural history and long-term functional out-
comes of such patients following invasive therapies. Indeed,
such follow-up remains critical in this highly active, other-
wise healthy patient population. The purpose of this study
was to assess the treatment evolution for idiopathic axillo-
subclavian vein thrombosis at Dartmouth-Hitchcock Med-
ical Center, and in doing so, document long-term overall
treatment patency and functional outcomes, measured as
sustained return to work and durable symptom relief.
METHODS
All patients treated for idiopathic axillo-subclavian vein
thrombosis from 1988 to 2008 were retrospectively iden-
tified from the Section of Vascular Surgery database at
Dartmouth-Hitchcock Medical Center. Neurogenic and
arterial thoracic outlet syndrome cases were excluded from
further review. Patients with catheter-induced upper ex-
tremity axillo-subclavian venous thromboses were not in-
cluded in the study cohort. Patient demographics, comor-
bidities, and operative technique were recorded. Overall
vein patency, freedom from reintervention, and functional
outcomes were the primary end points of the study. Clinic
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performed in all patients. A standardized interview was
performed in the clinic or by telephone with all patients to
assess functional outcomes, measured by sustained return
to work and durable symptom relief.
Statistical analysis. Overall vein patency throughout
the study interval and freedom from reintervention was
performed using Kaplan-Meier life table analysis with Stata
software (College Station, Tex).
RESULTS
Over the entire study interval (1988-2008), 65 patients
with a diagnosis of thoracic outlet syndromewere identified
and treated with comprehensive therapy including thoracic
outlet decompression surgery. Fifty-seven percent (N 
36) were treated for idiopathic axillo-subclavian vein
thrombosis, while 41% (N  26) were treated for neuro-
genic thoracic outlet syndrome. Three patients (2%) under-
went treatment for arterial thoracic outlet syndrome. Both
neurogenic and arterial thoracic outlet patients were ex-
cluded from further analysis. There was no substantial
change in the frequency of presentation of each respective
diagnosis to our institution over the study period.
Sixty-seven percent (N 24) of the patients were male,
with a mean age of 30 years (range, 17-51 years). Female
counterparts were only slightly older (mean, 34 years).
Eighty-three percent of treated cases were right sided, in
concordance with the prevalence of right-hand dominance.
Most patients were devoid of typically associated vascular
comorbidities. No patients were determined to have an
underlying hypercoaguable state (Table I).
Average time from the onset of symptoms to presenta-
tion at Dartmouth-Hitchcock Medical Center was 12 days
(range, 1-60 days). Eighty-three percent (N  30) of
patients underwent initiation of catheter-directed throm-
bolytic therapy throughout the study interval. All patients
were successfully lysed. Throughout the entire study, dif-
ferent lytic agents were utilized. Ten percent received
Streptokinase, reflecting the earliest experience using ante-
cedent lytic therapy. This was later supplanted over time by
Urokinase, in 33% of the cohort. More recently, the re-
maining 57% of our patients received tPA, as our treatment
protocol evolved. Currently, our thrombolytic therapy al-
gorithm involves ultrasound-guided ipsilateral upper ex-
Table I. Demographics and comorbidities
Male 67%
Mean age (male) 30 years (17-51)
Mean age (female) 34 years (14-54)
Right upper extremity 83%






Right upper extremity denotes the laterality of disease.tremity venous access. A multi-side holed catheter is ad-vanced across the thrombosed venous segment, and tPA
infusion is initiated (1 mg/hr), with subsequent reimaging
at 12-hour intervals to assess recanalization. There was no
difference in efficacy or observed lysis complications over
time among lytic agents including allergic reaction (N 1)
or hematoma formation (N  4). No patients required
transfusion or surgical exploration in the setting of their
hematomas.
Over the study interval, there has been a transition from
the well-described transaxillary approach to an infraclavic-
ular dissection technique. Specifically, 19 patients (52%)
underwent surgical decompression of the thoracic outlet
via a transaxillary approach. Eleven patients (31%) received
a supraclavicular surgical decompression, whereas the re-
maining six patients (17%) underwent surgery via an infra-
clavicular approach (Fig 1). Four patients underwent intra-
operative patch venoplasty in the setting of intrinsic venous
anatomic deformities including fibrotic scarring or webs.
No patients required transsternal extension of their inci-
sions for medial disease. Rather, 11 stents were placed in 11
patients for residual stenotic disease (defined as 50%
stenosis on completion venogram). Eight stents (73%) were
Fig 1. Surgical approach utilized throughout the study interval.
Historically, a greater percentage of patients underwent transaxil-
lary surgical decompression; however, more recently, an infracla-
vicular technique has been adopted.
Fig 2. Current multidisciplinary treatment algorithm for idio-
pathic axillo-subclavian vein thrombosis.placed intraoperatively, while one was placed preprocedur-
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placed postprocedurally, reflecting our earlier approach
using this percutaneous adjunct (Fig 2).
Overall, vein patency throughout the study interval was
determined by duplex ultrasound. Over the 20-year period,
durable patency was achieved, with 100% 1-year patency
and 94% 5-year patency, respectively (Fig 3). Likewise,
sustained freedom from reintervention was also observed,
with 100% freedom at 1-year and 77.4% at 5-year follow-up
(Fig 4).
Functional assessment was recorded for all patients
throughout the study using a standardized questionnaire/
interview. At the time of presentation, 65% (N  19) of
patients reported substantial impairment of their affected
extremity, citing inability to work, exercise, or perform
routine activities of daily living. Following aggressive treat-
Fig 3. Kaplan-Meier overall axillo-subclavian venous patency
throughout the study interval.
Fig 4. Kaplan-Meier freedom from reintervention throughout
the study interval.ment, only 14% (N  4) of patients admitted to ongoingimpairing symptoms. No patients experienced chronic arm
swelling over the course of the study interval.
DISCUSSION
This study is among the few to document long-term
patency and functional outcomes among patients with id-
iopathic axillo-subclavian vein thrombosis. Since its initial
description in the late 1800s, most studies have described
and documented therapeutic methodology for the effec-
tive management of effort-induced axillo-subclavian vein
thrombosis.1,3,6-10 Comparatively few have addressed
functional outcomes in these otherwise young, healthy,
active patients. Naturally, such outcomes have a profound
impact on the merits of any multidisciplinary therapy, re-
gardless of documented vein patency.
Currently, aggressive endovascular and open surgical
treatment is predicated on the presumption that afflicted
patients experience pervasive functional limitations. Histor-
ically, this posture may reflect an era of more limited
diagnostic capability, subsequently permitting less im-
paired patients to elude accurate diagnosis. Consequently,
it is likely that only a smaller subset of patients with more
progressive symptoms would seek consultation and treat-
ment. In their 2006 report, Persson et al document the
natural history of 31 contemporary patients with idiopathic
axillo-subclavian vein thrombosis treated with only antico-
agulation.11 Perhaps unexpectedly, the authors demon-
strated no association between the patients’ postthrom-
botic symptoms and their venous hemodynamics. The
authors, moreover, cite that 77% of patients in their study
experienced persistent symptoms, while only 30% pro-
gressed to moderate-grade postthrombotic syndrome fea-
tures. Unfortunately, it remains unclear from this study
whether the documented persistent symptoms precluded a
patient’s ability to return to work. This study, by compar-
ison, documents that 65% (N  19) of patients on presen-
tation were unable to perform their respective jobs due to
disabling symptoms. By comparison, only 14% (n  4) of
patients remained significantly impaired and unable to
work following multidisciplinary therapy. The natural his-
tory of patients treated without multimodal therapy was
not part of this study. Based on these findings, however,
one can infer that an indeterminate number of patients can
anticipate adequate function regardless of treatment, even
in the setting of a chronically occluded axillo-subclavian
vein. As reported by de Leon et al, many such patients with
chronically occluded axillo-subclavian veins will recanalize
while on anticoagulation, with resolution of their respective
symptoms over time.2 Despite this posture toward chroni-
cally impaired patients, this study demonstrates that a ma-
jority of patients who present acutely with symptoms caus-
ing impairment will benefit from aggressive therapy.
This study documents excellent long-term overall pa-
tency of the axillo-subclavian venous segment with aggres-
sive combined endovascular and open surgical treatment.
Over the study interval, our surgical approach has evolved
from the well-described transaxillary approach to an infra-
clavicular surgical technique. As documented by Molina et
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sure, thereby permitting circumferential dissection from
surrounding tissues and patch venoplasty when needed.12
Moreover, this surgical technique permits medial extension
across the manubrium to effectively treat residual stenoses.
Although Molina et al report that the partial transsternal
approach is well tolerated, this study validates the use of
stenting for treating residual medial stenoses, thereby ob-
viating the need for any surgical division of the sternum. As
described by Molina et al, we currently have adopted 8
weeks of formal anticoagulation with concomitant anti-
platelet therapy.12 Although no associated hypercoaguable
states were identified in this series, extended anticoagula-
tion treatment strategies would be favored accordingly in
this setting.
The role of stenting the venous segment has been the
subject of ongoing debate. Many remain unenthusiastic
about placing stents in the venous system, noting a
perceived inflammatory reaction, which may limit dura-
bility.2,7 Indeed, the use of catheter-based therapies as an
adjunct to surgical decompression therapy has been con-
troversial, especially among earlier reports. Green et al,
among others, have speculated that stent placement could
stimulate a hyperplastic response, thereby leading to re-
thrombosis.7 Alternatively, favorable outcomes have since
been described using stenting in the setting of idiopathic
axillo-subclavian vein thrombosis. Used selectively, stent-
ing has been utilized with moderate success. Kreinberg et al
cited a 64% stent patency over a mean follow-up period of
3.5 years.13 This study corroborates this finding, docu-
menting good overall patency at both 1 and 5 years among
patients treated with selective stenting for residual stenoses
(50%). Despite these findings, endoluminal stenting in
this setting reflects relatively small, single-center experi-
ences rather than large patient cohorts. Nevertheless, stent-
ing in this series did offer durable midterm results. Further-
more, if one considers the relatively benign natural history
of many patients with chronically occluded axillo-subcla-
vian venous segments,2 we maintain that stenting is prefer-
able to the alternative of partial sternotomy for treating
residual medial stenoses. Therefore, when used in combi-
nation with an infraclavicular technique, we propose the
“modified Molina” approach as the preferred treatment
method for patients with idiopathic axillo-subclavian vein
thrombosis. It should be noted, however, that this study is
not sufficiently powered to reach any definitive conclusions
on comparative long-term outcomes between stented and
unstented patients. It remains possible that stenting these
lesions may expedite short interval functional recovery,
while its role in chronic patient function remains less de-
fined, regardless of venous patency.
This study has several intrinsic limitations. First, this
remains a single-center retrospective study with a modest
size patient cohort, with seven patients lost to follow-up
over a 20-year period. It should be noted, however, that
historically, many series for idiopathic ASVT have been
relatively small in size. In addition, there was no standard-
ized treatment throughout the study interval. Patients weretreated according to surgeon discretion. Moreover, our
preferred treatment algorithm has evolved over time. Nev-
ertheless, this series does successfully document “real-
world” functional and treatment outcomes at a tertiary care
center. In addition, functional data were predicated on our
patient questionnaire and standardized telephone inter-
view. These questions were designed to capture a focused
assessment on the patient’s employment continuity, ability
to perform daily activities, sustained disability, and ongoing
narcotic/pain medication dependence. While not a “vali-
dated” questionnaire, this interview still offers a “valid”
depiction of a patient’s subjective disposition regarding his
or her respective functional status.
CONCLUSIONS
Based on our review of treatment for patients with
idiopathic axillo-subclavian vein thrombosis over a 20-year
interval, patients can expect durable overall patency with
sustained freedom from reintervention. Symptomatic pa-
tients with acute thromboses will experience substantial
functional improvement with a combined endovascular and
surgical approach using a selective stenting posture toward
treating residual medial venous stenoses. The natural his-
tory of patients with documented chronically occluded
axillo-subclavian veins remains somewhat unknown and
should be considered when considering aggressive surgical
intervention.
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